Vallon Pharmaceuticals, Inc. (VLON)
Market Cap | 34.06M |
Revenue (ttm) | 100,000 |
Net Income (ttm) | -4.22M |
Shares Out | 6.76M |
EPS (ttm) | -0.63 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | March 5 |
Last Price | $5.00 |
Previous Close | $5.30 |
Change ($) | -0.30 |
Change (%) | -5.64% |
Day's Open | 5.40 |
Day's Range | 4.90 - 5.44 |
Day's Volume | 72,821 |
52-Week Range | 4.90 - 9.90 |
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on th...
- Accomplished executive leader with more than 30 years of experience in finance and operations
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the ...
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs...
Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday.
Vallon Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.
About VLON
Vallon Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Industry Biotechnology | IPO Date Feb 10, 2021 |
CEO David Baker | Employees 2 |
Stock Exchange NASDAQ | Ticker Symbol VLON |